Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,497 across all filing types
Latest filing 2022-06-01 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
关于控股子公司拟发行新股并签署相关协议的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a capital financing transaction involving the issuance of new shares by a controlling subsidiary (Evive Biotech Ltd.) and the signing of related agreements. It includes comprehensive information about the transaction overview, parties involved, shareholding structures before and after the transaction, financial data of the companies involved, terms of the agreements, pricing policies, and risk disclosures. The document does not present a financial report such as an annual or interim report, nor is it a simple announcement of a report publication. It is not a regulatory filing or certification letter. The content clearly focuses on financing activities, specifically the issuance of new shares and capital injection to optimize capital structure and reduce debt. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (9658 characters) and detailed content support this classification with high confidence.
2022-06-01 Chinese
关于获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a drug registration certificate from the National Medical Products Administration. It details the approval of a pharmaceutical product, its specifications, and the impact on the company. The document is short (1394 characters) and serves as a formal announcement of a regulatory approval event rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or other report content. It is not an annual or interim report, earnings release, or any other detailed financial or governance document. Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-05-30 Chinese
2021年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2021 Annual General Meeting (AGM) of 亿帆医药股份有限公司. It includes information about the meeting date, attendance, voting results on various proposals including the annual report, financial statements, board elections, and other corporate governance matters. The document is not the annual report itself but the official announcement of the voting results and resolutions from the AGM. The length and detail confirm it is not a brief report publication announcement. The content matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-05-06 Chinese
关于回购注销部分限制性股票减少注册资本暨通知债权人的公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement by 亿帆医药股份有限公司 regarding the repurchase and cancellation of restricted shares under a 2019 stock incentive plan, which results in a reduction of registered capital. It details the board meetings approving these repurchases, the number of shares involved, the repurchase prices, and the impact on total share capital. Additionally, it includes a notification to creditors about the capital reduction and instructions for debt claims. The document is an official announcement of a share repurchase and capital change event, not a full financial report or audit. It is not a report publication announcement since it contains substantive details about the transaction. Therefore, the appropriate classification is a Share Issue/Capital Change announcement (SHA). The document length is under 5,000 characters but contains detailed transaction information, so it is not a mere announcement of a report publication (RPA).
2022-05-06 Chinese
第八届监事会第一次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement regarding the resolution of the first (extraordinary) meeting of the eighth Supervisory Board of Yifan Pharmaceutical Co., Ltd. It details the election of the Supervisory Board chairman, meeting attendance, and compliance with company law and articles of association. There is no financial data, no mention of financial results, no audit report, no shareholder voting results from a general meeting, and no reference to any report publication. The document is an official announcement about board-level management changes, specifically the election of a Supervisory Board chairman. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on management changes, not a full report or financial disclosure.
2022-05-06 Chinese
安徽天禾律师事务所关于亿帆医药股份有限公司2021年年度股东大会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2021 Annual General Meeting (AGM) of Yifan Pharmaceutical Co., Ltd. It details the procedures of convening and holding the AGM, the qualifications of attendees, the voting procedures, the proposals considered, and the voting results. It confirms the legality and validity of the AGM and its resolutions. The document is not the AGM materials or presentations themselves, but a legal opinion on the AGM process and outcomes. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports official results from shareholder votes at the AGM. The document length is substantial and contains detailed voting results and legal opinions, not just an announcement of a report or a brief notice. Therefore, the classification is DVA with high confidence.
2022-05-06 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.